Zhong-Yin Zhang, head of Purdue’s Department of Medicinal Chemistry and Molecular Pharmacology, developed highly potent and selective compounds for use in the treatment of tuberculosis.
Purdue University innovators have developed highly potent and selective compounds for use in the treatment of tuberculosis, which is one of the top 10 causes of death worldwide.
The Purdue researchers developed a series of small molecule inhibitors to target one of the proteins critical for the survival of TB in infected macrophages. Protein tyrosine phosphates B (mPTPB) is a virulence factor of TB to subvert the host immune responses.
The Purdue research is published in the Journal of Medicinal Chemistry.
“The death toll from TB is particularly high because of drug-resistant strains,” said Zhong-Yin Zhang, distinguished professor and head of Purdue’s Department of Medicinal Chemistry and Molecular Pharmacology and director of Purdue Institute for Drug Discovery. “These inhibitors are part of a promising new approach to developing TB therapeutic agents with novel targets and mechanisms of action to help save more lives.”
Current treatments for TB are mostly antibiotic-based solutions. A major problem is that a large number of patients fail to take the entire antibiotic regime, which can lead to drug-resistant strains.
“We developed a platform to target mPTPB for novel anti-TB agents that builds on technologies we pioneered to modulate abnormal protein tyrosine phosphatase activity for the treatment of diseases such as cancer, diabetes and autoimmune disorders,” Zhang said.
Zhang said these inhibitors’ properties also make them promising drug candidates. They possess lighter molecular weights, excellent metabolic stability and bioavailability to provide a starting point for further therapeutic development for use as TB treatments.
The innovators and OTC are looking for partners to continue developing their technology. For more information on licensing and other opportunities, contact Joseph Kasper of OTC at [email protected] and mention track code 2020-ZHAN-68995.
Original Article: New inhibitors may offer novel approach to treating deadly tuberculosis
More from: Purdue University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Tackling TB: A new trial is asking how to take tuberculosis tests to the peopleon April 29, 2021 at 3:32 pm
Roughly two in five people newly ill with TB worldwide are never diagnosed. In South Africa, this amounts to about 120,000 to 160,000 people per year. Now, a new study called XACT III is testing ways ...
- The tuberculosis pathogen releases its toxin via a novel protein transport systemon April 29, 2021 at 8:38 am
Six years ago, scientist Michael Niederweis described the first toxin ever found for the deadly pathogen Mycobacterium tuberculosis. The toxin, tuberculosis necrotizing toxin or TNT, became the ...
- Patralekhaa recalls battling tuberculosis at teenage as she pens a gratitude letter for her late fatheron April 29, 2021 at 3:02 am
Actor Patralekhaa who recently lost her father Ajit Paul, took to her social media handles to share a long letter to her late father which has been pe ...
- Tuberculosis Diagnostics Market Research Report by Test Type, by Type, by End_User - Global Forecast to 2025 - Cumulative Impact of COVID-19on April 29, 2021 at 2:22 am
This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Tuberculosis Diagnostics Market is expected to grow from USD 2,591.77 Million in ...
- Dr. Marty Makary: ‘More People Have Tuberculosis Than Coronavirus Right Now in the United States’on April 28, 2021 at 7:53 am
Dr. Marty Makary, Johns Hopkins University professor of public health, said Wednesday that there are more people with tuberculosis right now in the United States than those with COVID-19.
Go deeper with Google Headlines on:
No news articles
Go deeper with Bing News on:
Small molecule inhibitors
- BeyondSpring Inc. (BYSI) Q1 2021 Earnings Call Transcripton April 30, 2021 at 3:01 pm
Q1 2021 Earnings CallApr 30, 2021, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and welcome to BeyondSpring's Fourth Quarter ...
- ChemoCentryx Inc (CCXI) Q1 2021 Earnings Call Transcripton April 30, 2021 at 3:01 pm
Q1 2021 Earnings CallApr 30, 2021, 9:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day and thank you for standing by. Welcome to the ...
- Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoiron April 30, 2021 at 2:48 am
DEAD-box polypeptide 3 (DDX3) is a host protein belonging to the family of ATP-dependent RNA helicases. Here, the authors demonstrate that DDX3 inhibitors reverse HIV-1 latency and selectively induce ...
- The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitorson April 29, 2021 at 9:01 am
CoV-2, which is the etiological agent at the origin of the COVID-19 pandemic, requires a main protease M pro to cleave the virus-encoded polyproteins. Despite a wealth of experimental information ...
- EMA to quickly review Eli Lilly, Incyte arthritis drug for COVID-19 useon April 29, 2021 at 8:40 am
The European Medicines Agency will conduct an accelerated review of Eli Lilly and Co's rheumatoid arthritis drug Olumiant for hospitalized COVID-19 patients getting oxygen, the agency said on Thursday ...